Science is getting better at re-engineering micro-organisms for all kinds of uses, from better medical treatments to more durable materials. But there are still hurdles to overcome, including scaling the process.

Boston-based Ginkgo Bioworks was one of the first billion-dollar companies in the synthetic biology space. The NYSE-listed company uses machine learning and automation to coax biology to work at industrial scale. COO Reshma Shetty talks to Azeem Azhar about the company’s technology, business model, and how big she thinks synthetic biology could become.

@Azeem

Further resources:

The Bio Revolution: Innovations transforming economies, societies, and our lives – McKinsey, May 2020

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.